The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment

Hepatology Research

Volumn 46, Issue 11, 2016, Pages 1074-1087

  Ballestri, Stefano ^a   Nascimbeni, Fabio ^a   Romagnoli, Dante ^a   Lonardo, Amedeo ^a  

^a AUSL Modena   (Italy)

Author keywords

fibrosis; HOMA IR; inflammatory grading; iron; NAFLD; steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; INSULIN; IRON; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; IRON BLOOD LEVEL; LABORATORY TEST; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84993675348     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12656     Document Type: Article

References (57)

1. Nascimbeni F, Pais R, Bellentani S et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859–71.
2. Non-alcoholic fatty liver disease (NAFLD) study group, dedicated to the memory of Prof. Paola Loria, Lonardo A et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 47: 997–1006.
3. Baumeister SE, Völzke H, Marschall P et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134: 85–94.
4. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617–49.
5. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 2013; 19: 5177–92.
6. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724–45.
7. Brunt EM, Janney CG, Di Bisceglie, AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–74.
8. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–23.
9. Angulo P, Kleiner DE, Dam-Larsen S et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149: 389–97.e10.
10. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007–19.
11. Loria P, Adinolfi LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42: 272–82.
12. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
13. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810–20.
14. Younossi ZM, Stepanova M, Rafiq N et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874–82.
15. Ballestri S, Lonardo A, Loria P. Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree? Hepatology 2011; 53: 2142–3.
16. Brunt EM, Kleiner DE, Wilson LA et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809–20.
17. Rakha EA, Adamson L, Bell E et al. Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. J Clin Pathol 2010; 63: 790–5.
18. Gadd VL, Skoien R, Powell EE et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 2014; 59: 1393–405.
19. Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77–85.
20. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901–10.
21. Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol 2014; 8: 487–500.
22. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181–90.
23. Neuschwander-Tetri BA, Clark JM, Bass NM et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913–24.
24. Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34: 757–66.
25. Sertoglu E, Ercin CN, Celebi G et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem 2014; 47: 383–8.
26. Levey AS, Coresh J, Greene T et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–54.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
28. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: Clinical practice recommendations. Diabetes Care 2002; 25: S1–S147.
29. Mancia G, Fagard R, Narkiewicz K, et al. Guidelines for the management of arterial hypertension: The Task Force for theManagement of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
30. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–5.
31. Bedossa P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014; 60: 565–75.
32. Larrain S, Rinella ME. A myriad of pathways to NASH. Clin Liver Dis 2012; 16: 525–48.
33. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in non-alcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011; 5: 279–89.
34. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol 2015; 62: 1148–55.
35. Lonardo A, Loria P, Leonardi F et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case control study. Dig Liver Dis 2002; 34: 204–11.
36. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009; 50: 1029–34.
37. Keenan T, Blaha MJ, Nasir K et al. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol 2012; 110: 1787–92.
38. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013; 62: 392–9.
39. Zelber-Sagi S, Ben-Assuli O, Rabinowich L et al. The association between serum levels of uric-acid and alanine aminotransferase in a population-based cohort. Liver Int 2015; 35: 2408–15.
40. Hossain N, Afendy A, Stepanova M et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224–9, 1229.e1–2.
41. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–23.
42. Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci 2014; 11: 925–35.
43. Carulli L, Ballestri S, Lonardo A et al. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med 2013; 8: 297–305.
44. Van Rooyen DM, Larter CZ, Haigh WG et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393–403, 1403.e1–5.
45. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013; 52: 175–91.
46. Ioannou GN, Haigh WG, Thorning D, Savard C. Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. J Lipid Res 2013; 54: 1326–34.
47. Tomita K, Teratani T, Suzuki T et al. Free cholesterol accumulation inhepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014; 59: 154–69.
48. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898–904.
49. Lonardo A, Loria P. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 36: 514–5.
50. Fujita K, Nozaki Y, Wada K et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009; 50: 772–80.
51. Loria P, Marchesini G, Nascimbeni F et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014; 232: 99–109.
52. Van Rooyen DM, Gan LT, Yeh MM et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59: 144–52.
53. Bazick J, Donithan M, Neuschwander-Tetri BA et al. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care 2015; 38: 1347–55.
54. Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 37: 720–9.
55. Valenti L, Fracanzani AL, Dongiovanni P. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002–10.
56. Adams LA, Crawford DH, Stuart K et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology 2015; 61: 1555–64.
57. Nascimbeni F, Bedossa P, Fedchuck L et al. Clinical validation of the FLIP algorithm and SAF score in non-alcoholic fatty liver disease. J Hepatol 2014; 60: S348.